Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
80.28%
Net Margin
157.20%
Efficiency Metrics
Revenue per Expense Ratio
5.07
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
2.3400000000
Balance Sheet Analysis
Current Ratio
1.21
Cash Ratio
0.01
Working Capital
$549.58K
Debt to Equity
0.28
Debt to Assets
21.52%
Equity Ratio
77.68%
Cash Flow Analysis
Operating Cash Flow Ratio
110.73%
Free Cash Flow Ratio
110.73%
CapEx to Revenue
0.00%
Dividends Paid
$27.02M
Stock Buybacks
No buybacks
Total Shareholder Returns
$27.02M
Cash Position Change
104.00%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
120.75%
Net Income
132.47%
EPS
132.45%
Operating Income
116.84%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
844.86%
Operating Cash Flow
8.01%
Free Cash Flow
8.01%
Balance Sheet Health
Assets
3.06%
Debt
0.00%
Book Value per Share
3.15%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-21.16%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
249.86%
5Y Revenue/Share
698.06%
3Y Dividend/Share
-12.94%
5Y Dividend/Share
-5.71%